First-line nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 2-year follow-up

被引：2
|
作者：
Shen, L. [1 ]
Bai, Y. [2 ]
Lin, X. [3 ]
Li, W. [4 ]
Wang, J. [5 ]
Zhang, X. [6 ]
Pan, H. [7 ]
Bai, C. [8 ]
Bai, L. [9 ]
Cheng, Y. [10 ]
Zhang, J. [11 ]
Zhong, H. [12 ]
Ba, Y. [13 ]
Hu, W. [14 ]
Xu, R. [15 ]
Guo, W. [16 ]
Qin, S. [17 ]
Yang, N. [18 ]
Lu, J. [19 ]
Chanaga, C. Amaya [20 ]
Soleymani, S. [20 ]
Liu, T. [21 ]
机构：
[1] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[2] Herbin Med Univ, Harbin, Heilongjiang, Peoples R China
[3] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China
[4] Jilin Univ, Hosp 1, Changchun, Peoples R China
[5] Henan Canc Hosp, Zhengzhou, Peoples R China
[6] Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China
[7] Sir Run Shaw Hosp, Hangzhou, Peoples R China
[8] Peking Union Med Coll Hosp, Beijing, Peoples R China
[9] China PLA Gen Hosp, 301 Hosp, Beijing, Peoples R China
[10] Jilin Canc Hosp, Changchun, Peoples R China
[11] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[12] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[13] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[14] First Peoples Hosp Changzhou, Changzhou, Jiangsu, Peoples R China
[15] Sun Yat Sen Univ, Med Oncol Canc Ctr, Guangzhou, Peoples R China
[16] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[17] Eastern Theater Gen Hosp, QinHuai Dist Med Area, Nanjing, Peoples R China
[18] Hunan Canc Hosp, Changsha Shi, Peoples R China
[19] Jiangsu Canc Hosp, Nanjing, Peoples R China
[20] Bristol Myers Squibb, Princeton, NJ USA
[21] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.04.176
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-86
引用
收藏
页码：S279 / S279
页数：1
相关论文
共 50 条
  • [21] Real-world (RW) effectiveness of nivolumab plus chemotherapy (NIVO plus chemo) in patients (pts) with advanced or metastatic gastric carcinoma, gastroesophageal junction carcinoma, or esophageal adenocarcinoma (GC/GEJC/EAC)
    Chau, Ian
    Barzi, Afsaneh
    Zhang, Ying
    You, Min
    Bertwistle, David
    Davis, Catherine
    Chen, Clara
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 295 - 295
  • [22] Number needed to treat (NNT) analysis of patients in CheckMate 649 (CM 649): Nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJ/EAC)
    Sugarman, Ryan
    Nunna, Sasikiran
    Betts, Keith A.
    Nie, Xiaoyu
    Nguyen, Hiep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [23] Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N plus C) versus chemo (C)
    Moehler, M.
    Wyrwicz, L.
    Chen, C.
    Davenport, E.
    Wang, J.
    Nathani, R.
    Kondo, K.
    Elimova, E.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S185 - S185
  • [24] Q-TWiST analysis of nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC) in patients with PD-L1 CPS≥1 and CPS≥5: 4-year follow-up from CheckMate 649 (CM 649)
    Lin, D.
    Quan, W.
    Garretson, M.
    Chirikov, V. V.
    Chen, C.
    Singh, P.
    Davis, C.
    Sugarman, R.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : S170 - S170
  • [25] Updated quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of nivolumab plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC): 4-year (yr) follow-up from CheckMate 649 (CM 649)
    Lin, Daniel
    Quan, Wenying
    Garretson, Marne
    Chirikov, Viktor
    Chen, Clara
    Singh, Prianka
    Davis, Catherine
    Sugarman, Ryan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649
    Moehler, M.
    Elimova, E.
    Blum, S., I
    Xiao, H.
    Davenport, E.
    Wang, J.
    Hunter, S.
    Li, M.
    Kondo, K.
    Wyrwicz, L.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 214 - 215
  • [27] First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.
    Shiu, Kai-Keen
    Rivera, Fernando
    Medley, Louise C.
    Aghmesheh, Morteza
    Dunne, Richard Francis
    Roy, Rajarshi
    Wyrwicz, Lucjan S.
    Larson, Timothy
    Metges, Jean-Philippe
    Mansoor, Wasat
    Goekkurt, Eray
    Moreira Antunes, Luiz Carlos
    Castro Oliden, Victor
    Jensen, Erin
    Shah, Sukrut
    Bordia, Sonal
    Bhagia, Pooja
    Lowery, Maeve Aine
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 345 - 345
  • [28] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649.
    Wyrwicz, Lucjan
    Elimova, Elena
    Blum, Steven I.
    Xiao, Hong
    Davenport, Eric
    Wang, Jinyi
    Hunter, Shannon
    Li, Mingshun
    Kondo, Kaoru
    Moehler, Markus H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/ gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): 36-month results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649
    Elimova, Elena
    Wyrwicz, Lucjan
    Chen, Clara
    Blum, Steven Michael
    Davenport, Eric
    Wang, Jinyi
    Kondo, Kaoru
    Moehler, Markus H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: a cost-effectiveness analysis
    Cao, Xueqiong
    Zhang, Mingming
    Li, Na
    Zheng, Bin
    Liu, Maobai
    Song, Xiaobing
    Cai, Hongfu
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
12345